The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
Stay updated with the latest insights and developments in cancer care.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Breakthrough Study Shows CAR T Cells Can Be Generated Inside The Body
By The Cancer News Team
Researchers have developed a new method for generating CAR T cells inside the body using targeted lipid nanoparticles, potentially eliminating barriers that contribute to cancer health disparities.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
Can Exercise Save Lives After Colon Cancer? New Study Suggests It Might
By The Cancer News Team
A landmark phase 3 trial shows structured exercise after chemotherapy significantly improves survival and reduces recurrence in colon cancer patients.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
Basic Science & Molecular Pathogenesis of Lung Cancer
By Editorial Team
**_Presented by:_** Alex A. Adjei, MD, PhD, FACP **_Covered by_**_:_ Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. \[caption id="attachm...
Basic Science & Molecular Pathogenesis of Lung Cancer
By Editorial Team
**_Presented by:_** Alex A. Adjei, MD, PhD, FACP **_Covered by_**_:_ Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. \[caption id="attachm...
Basic Science & Molecular Pathogenesis of Lung Cancer
By Editorial Team
**_Presented by:_** Alex A. Adjei, MD, PhD, FACP **_Covered by_**_:_ Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. \[caption id="attachm...
Basic Science of Precision Oncology in GU Oncology
By Editorial Team
**_Presented by:_** Russell K Pachynski M.D, Associate Professor and Director of GU Oncology Research at The Division of Oncology, Siteman Cancer Center Washington University School of Medicine, St Lo...
Basic Science of Precision Oncology in GU Oncology
By Editorial Team
**_Presented by:_** Russell K Pachynski M.D, Associate Professor and Director of GU Oncology Research at The Division of Oncology, Siteman Cancer Center Washington University School of Medicine, St Lo...
Basic Science of Precision Oncology in GU Oncology
By Editorial Team
**_Presented by:_** Russell K Pachynski M.D, Associate Professor and Director of GU Oncology Research at The Division of Oncology, Siteman Cancer Center Washington University School of Medicine, St Lo...